Study on the hepatocytic cell targetability of liposomes / 药学学报
Acta Pharmaceutica Sinica
;
(12): 143-146, 2003.
Artículo
en Chino
| WPRIM
| ID: wpr-251155
ABSTRACT
<p><b>AIM</b>To target for hepatocytic cell, liposomes was modified by special ligand.</p><p><b>METHODS</b>Sterically stabilized liposomes (SSL) was conjugated with asialofeticin (AF), the ligand of asialoglycoprotein receptor (ASGP-R) of hepatocyte. ASGP-R-BLM is the ASGP-R reconstructed on bilayer lipid membrane (BLM). The recognition reaction between AF-SSL and ASGP-R-BLM can be monitored by the varieties of membrane electrical parameters. The targetability of AF-SSL mediated to hepatocyte was detected by radioisotopic labeled in vitro and in vivo. The therapeutic effect of antihepatocarcinoma was observed also.</p><p><b>RESULTS</b>The lifetime of ASGP-R-BLM decreased with the added amount of AF-SSL. It was demonstrated that there was recognition reaction between AF-SSL and ASGP-R-BLM. The combination of AF-SSL with hepatocyte was significantly higher than that of SSL without AF-modified in vitro and in vivo. The survival time of rat for AF-SSL carriered ADM (adriamycin) group was much longer and the toxicities on heart, kidney and lung were lower than those SSL carried ADM group.</p><p><b>CONCLUSION</b>It is possible to actively target the cell with specific receptor by ligand modified liposomes. The result prvide scientific basis of hepatocyte targeted liposomes.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Asialoglicoproteínas
/
Portadores de Fármacos
/
Alfa-Fetoproteínas
/
Doxorrubicina
/
Distribución Aleatoria
/
Química
/
Sistemas de Liberación de Medicamentos
/
Hepatocitos
/
Receptor de Asialoglicoproteína
/
Usos Terapéuticos
Límite:
Animales
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS